Unicycive Stock Soars 835.63% on Upcoming Data Presentation

On June 20, 2025, Unicycive's stock surged by an astonishing 835.63% in pre-market trading, marking a significant milestone for the biotechnology company.

Unicycive Therapeutics, Inc. recently announced that it will present patient-reported outcomes data at an upcoming event. This development is expected to provide valuable insights into the efficacy and safety of the company's clinical-stage therapies, potentially influencing investor sentiment and market perception.

Additionally, Unicycive is awaiting a decision by the FDA with a PDUFA action date set for June 28, 2025. This regulatory milestone is crucial for the company's pipeline, as a positive outcome could accelerate the development and commercialization of its innovative treatments, further driving investor interest and stock performance.